Testosterone and Prostate Health: What the Research Actually Shows

For decades, men have been told, directly or implicitly, that testosterone is dangerous to the prostate. The logic seemed straightforward: prostate cancer responds to androgens, testosterone is an androgen, therefore more testosterone must mean more prostate cancer. Modern research has complicated that story. The picture today is reassuring in some respects and unsettled in others, and neither “testosterone causes prostate cancer” nor “the risk is fully debunked” is an accurate summary. This article is educational, not medical advice, and anyone with prostate concerns should speak with a doctor.

Where the Concern Came From: Huggins 1941

The fear of testosterone and prostate cancer traces to the work of Dr. Charles Huggins, who won the Nobel Prize in 1966. In 1941 he reported that castration, and the resulting near-elimination of testosterone, was followed by regression of metastatic prostate cancer, and that injecting androgens in these men was followed by progression.^[5] This was a breakthrough that made androgen deprivation therapy a cornerstone of advanced prostate cancer treatment.

However, a logical leap followed: because removing testosterone shrank prostate cancer, it was assumed that higher testosterone in men with normal levels must cause or promote it. That is a different question from the one Huggins studied, which involved men with established, advanced cancer and testosterone driven to near zero. Whether normal or higher testosterone causes prostate cancer in men who do not have it requires different kinds of evidence, and that is what the later studies tried to address.

The Saturation Model: A Proposed Framework

The model offers a coherent explanation for why castration shrinks prostate cancer but studies of normal-range testosterone have not found strong effects. It is, however, a hypothesis and not a settled fact. A 2020 review examined the evidence cited when the model was first presented and concluded that it was in many cases taken out of context, advising caution in applying the model to men with prostate cancer.^[7] Treat it as one useful framework, not as proof that testosterone cannot affect the prostate.

What Large-Scale Studies Show

No single study answers this question, so it helps to look at the different kinds of evidence together:

The Endogenous Hormones and Prostate Cancer Collaborative Group pooled 18 prospective studies with 3,886 men who developed prostate cancer and 6,438 controls. No associations were found with total testosterone, calculated free testosterone, DHT, estradiol and several other hormones, while higher SHBG was modestly associated with lower risk (relative risk 0.86 for the highest versus lowest fifth).^[1] A 2026 individual-participant meta-analysis of prospective cohorts found that total testosterone was not associated with incident prostate cancer in five studies covering 12,280 men, while lower SHBG and lower luteinising hormone were associated with higher risk.^[8]

Randomized evidence on testosterone treatment is more limited. In the TRAVERSE trial, 5,204 men aged 45 to 80 with low testosterone and cardiovascular disease or risk were randomized to testosterone gel or placebo. High-grade prostate cancer occurred in 5 of 2,596 men on testosterone (0.19%) and 3 of 2,602 on placebo (0.12%), which was not a significant difference, and rates of any prostate cancer, urinary retention, biopsies and procedures also did not differ significantly. PSA rose more in the testosterone group.^[2] With so few events and an average follow-up under two years, the trial cannot rule out a longer-term effect.

More recent work adds a note of caution. Using prospective data from up to 25 studies (14,944 cases) and genetic (Mendelian randomization) analyses, researchers found that higher free testosterone was associated with overall prostate cancer (odds ratio 1.20 per standard deviation in the genetic analysis) and with aggressive disease (1.23), while total testosterone and SHBG were not clearly associated in the genetic analyses.^[3] The effect sizes are modest, and genetic estimates reflect lifelong differences rather than short-term treatment, but they are a reason not to claim that testosterone is completely irrelevant to prostate cancer risk.

BPH vs. Prostate Cancer: An Important Distinction

Benign prostatic hyperplasia (BPH) and prostate cancer are often conflated in discussions about testosterone and the prostate, but they are distinct conditions. BPH is a non-cancerous enlargement of the prostate that is very common with age: a pooled analysis of autopsy studies found pathological BPH in about 8% of men in their thirties and 50% of men aged 51 to 60.^[9] It mainly causes urinary symptoms such as a weak stream, frequent urination and nighttime waking, whereas prostate cancer involves malignant cell growth that can spread. PSA can be raised by either condition.

Testosterone is converted to DHT in prostate tissue by the enzyme 5-alpha reductase, and DHT contributes to prostate growth. That is why 5-alpha reductase inhibitors such as finasteride are used to treat BPH. On testosterone and urinary symptoms, a meta-analysis of 14 randomized trials with 2,029 men (average age 64.5, average follow-up about 34 months) found no significant difference in change in urinary symptom scores between men treated with testosterone and those on placebo, suggesting that treatment did not worsen symptoms in men with low testosterone.^[10] Those results apply to men with diagnosed low testosterone under medical care, not to people taking hormones on their own. For a related discussion, see our article on testosterone, DHT, and hair loss.

PSA Monitoring: What Men Should Know

Prostate-specific antigen (PSA) is a protein produced by prostate tissue. PSA can be elevated by prostate cancer, BPH, prostatitis (inflammation), and other factors, so an elevated PSA does not automatically mean cancer, and a normal PSA does not guarantee its absence. The AUA/SUO guideline recommends PSA-based screening combined with shared decision-making, and notes that current data support longer screening intervals and tailored, risk-based screening.^[11] It suggests clinicians may offer a baseline PSA test to people aged 45 to 50 and should offer screening beginning at age 40 to 45 for people at increased risk, including Black men, men with germline mutations and men with a strong family history.^[11] Whether to be screened is a decision for you and your doctor, and it applies whether or not you are interested in testosterone.

When to Be Cautious

These recommendations come from the Endocrine Society guideline on testosterone therapy in men with hypogonadism and from the AUA/SUO screening guideline.^[4,11]

The Bottom Line

The old belief that normal testosterone levels feed prostate cancer is not supported by the strongest pooled evidence, and testosterone treatment in men with low levels has not shown a clear prostate signal in randomized trials so far. At the same time, some newer analyses suggest free testosterone may be modestly linked to prostate cancer risk, trial follow-up has been short, and the saturation model is a debated hypothesis. The responsible position is neither alarm nor a guarantee of safety.

The evidence discussed here concerns blood hormone levels and medically supervised treatment, not everyday habits. Practices like sleep, exercise, nutrition, and stress management are recommended for general health and are covered in our guide to increasing testosterone naturally. Whatever you do, follow standard prostate screening advice for your age and risk, and see a doctor about urinary symptoms or a family history of prostate cancer.

Related Reading

• Testosterone Levels by Age: how testosterone changes across adult life.
• Signs of Low Testosterone: symptoms that are worth discussing with a doctor.

How Thrive Helps

Thrive helps you build evidence-based lifestyle habits, from sleep and training to nutrition and stress management, and see how they add up over time. It does not diagnose, treat or screen for any condition. If you have prostate or urinary concerns, see a doctor. Try Thrive and build your routine on science, not fear. Thrive is a wellness app, not a medical device.